Patients with BRCA1/2 mutations had notably worse outcomes than non-HR or non-BRCA patients (p < 0.05), and progression-free survival and overall survival were remarkably shorter for BRCA than HR or non-BRCA patients (p < 0.05), suggesting a role for appropriate genetic screening to improve PCa prognosis [40]. The gene discussed is BRCA1; the disease is posterior cortical atrophy.